{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:22:48Z","timestamp":1791285768931,"version":"4.1.0"},"reference-count":39,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT"],"published-print":{"date-parts":[[2014]]},"DOI":"10.5551\/jat.21410","type":"journal-article","created":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T22:58:18Z","timestamp":1397429898000},"page":"868-877","source":"Crossref","is-referenced-by-count":8,"title":["Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients"],"prefix":"10.5551","volume":"21","author":[{"given":"Bosa","family":"Mirjanic-Azaric","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Vekic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Zeljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zorana","family":"Jelic-Ivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Djeric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Milivojac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursa","family":"Pecar Fonovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janja","family":"Marc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janko","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Cerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP: Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol, 2004; 24: 359-366","DOI":"10.1161\/01.ATV.0000134530.27208.41"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Cheng XW, Huang Z, Kuzuya M, Okumura K, Murohara T: Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension, 2011; 58: 978-986","DOI":"10.1161\/HYPERTENSIONAHA.111.180935"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P: Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest, 1998; 102: 576-583","DOI":"10.1172\/JCI181"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Jormsj\u00f6 S, Wuttge D, Sirsj\u00f6 A, Whatling C, Hamsten A, Stemme S, Eriksson P: Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E- deficient mice. Am J Pathol, 2002; 161: 939-945","DOI":"10.1016\/S0002-9440(10)64254-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S: Cathepsin cysteine proteases in cardiovascular disease. FASEB J, 2007; 21: 3029-3041","DOI":"10.1096\/fj.06-7924com"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Sukhova GK, Zhang Y, Pan JH, Wada Y, Yamamoto T, Naito M, Kodama T, Tsimikas S, Witztum JL, Lu ML, Sakara Y, Chin MT, Libby P, Shi GP: Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest, 2003; 111: 897-906","DOI":"10.1172\/JCI14915"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) de Nooijer R, Bot I, von der Th\u00fcsen JH, Leeuwenburgh MA, Overkleeft HS, Kraaijeveld AO, Dorland R, van Santbrink PJ, van Heiningen SH, Westra MM, Kovanen PT, Jukema JW, van der Wall EE, van Berkel TJ, Shi GP, Biessen EA: Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis. Arterioscler Thromb Vasc Biol, 2009; 29: 188-194","DOI":"10.1161\/ATVBAHA.108.181578"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Rodgers KJ, Watkins DJ, Miller AL, Chan PY, Karanam S, Brissette WH, Long CJ, Jackson CL: Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol, 2006; 26: 851-856","DOI":"10.1161\/01.ATV.0000203526.75772.4b"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Liu J, Ma L, Yang J, Ren A, Sun Z, Yan G, Sun J, Fu H, Xu W, Hu C, Shi GP: Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis, 2006; 186: 411-419","DOI":"10.1016\/j.atherosclerosis.2005.08.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Cerne D, Stern I, Marc J, Cerne A, Zorman D, Krzisnik-Zorman S, Kranjec I: CTSS activation coexists with CD40 activation in human atheroma: evidence from plasma mRNA analysis. Clin Biochem, 2011; 44: 438-440","DOI":"10.1016\/j.clinbiochem.2011.01.003"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Abisi S, Burnand KG, Humphries J, Waltham M, Taylor P, Smith A: Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms. Br J Surg, 2008; 95: 333-337","DOI":"10.1002\/bjs.5989"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Qin YW, Ye P, He JQ, Sheng L, Wang LY, Du J: Simvastatin inhibited cardiac hypertrofi and fibrosis in apolipoprotein E-deficient mice fed a \u201cWestern-style diet\u201d by increasing PPAR \u03b1 and \u03b3 expression and reducing TC, MMP-9, and Cat S levels. Acta Pharmacol Sin, 2010; 31: 1350-1358","DOI":"10.1038\/aps.2010.109"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Stern I, Marc J, Kranjec I, Zorman D, Cerne A, Cerne D: Increased plasma levels of CATS mRNA but not CATB mRNA in patients with coronary atherosclerosis. Clin Biochem, 2010; 43: 1427-1430","DOI":"10.1016\/j.clinbiochem.2010.09.017"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Lindstedt L, Lee M, \u00d6\u00f6rni K, Br\u00f6mme D, Kovanen PT: Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. Biochem Biophys Res Commun, 2003; 312: 1019-1024","DOI":"10.1016\/j.bbrc.2003.11.020"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Hakala JK, Oksjoki R, Laine P, Du H, Grabowski GA, Kovanen PT, Pentik\u00e4inen MO: Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extra cellularly in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 2003; 23: 1430-1436","DOI":"10.1161\/01.ATV.0000077207.49221.06"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Lutgens E, Lutgens SP, Faber BC, Heeneman S, Gijbels MM, de Winther MP, Frederik P, van der Made I, Daugherty A, Sijbers AM, Fisher A, Long CJ, Saftig P, Black D, Daemen MJ, Cleutjens KB: Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation, 2006; 113: 98-107","DOI":"10.1161\/CIRCULATIONAHA.105.561449"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marko J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL: Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J, 2006; 27: 1341-1381","DOI":"10.1093\/eurheartj\/ehl001"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Mirjanic-Azaric B, Rizzo M, Sormaz L, Stojanovic D, Uletilovic S, Sodin-Semrl S, Lakota K, Artenjak A, Marc J, Cerne D: Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: Pleiotropic evidence from plasma mRNA analyses. Clin Biochem, 2013; 46: 1526-1531","DOI":"10.1016\/j.clinbiochem.2013.06.006"},{"key":"19","unstructured":"19) Cerne D, Stern I, Kranjec I, Marc J: Optimisation of methods for quantifying plasma mRNA levels from genes responsible for coronary artery plaque development and destabilization. Med Glas (Zenica), 2011; 8: 90-96"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) Method. Methods, 2001; 25: 402- 408","DOI":"10.1006\/meth.2001.1262"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kos J, Sekirnik A, Kopitar G, Cimerman N, Kayser K, Stremmer A, Fiehn W, Werle B: Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Brit J Cancer, 2001; 85: 1193-1200","DOI":"10.1054\/bjoc.2001.2057"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Rainwater DL, Andres DW, Ford AL, Lowe WF, Blanche PJ, Krauss RM: Production of polyacrylamide gradient gels for the electrophoretic resolution of lipoproteins. J Lipid Res, 992; 33: 1876-1881","DOI":"10.1016\/S0022-2275(20)41346-X"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Vekic J, Topic A, Zeljkovic A, Jelic-Ivanovic Z, SpasojevicKalimanovska V: LDL and HDL subclasses and their relationship with Framingham risk score in middle-aged Serbian population. Clin Biochem, 2007; 40: 310-316","DOI":"10.1016\/j.clinbiochem.2006.11.013"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Zeljkovic A, Spasojevic-Kalimanovska V, Vekic J, JelicIvanovic Z, Topic A, Bogavac-Stanojevic N, Spasic S, Vujovic A, Kalimanovska-Ostric D: Does simultaneous determination of LDL and HDL particle size improve prediction of coronary artery disease risk? Clin Exp Med, 2008; 8: 109-116","DOI":"10.1007\/s10238-008-0165-z"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, JelicIvanovic Z, Bogavac-Stanojevic N, Gulan B, Spasic S: LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis, 2010; 210: 548-554","DOI":"10.1016\/j.atherosclerosis.2009.11.040"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Katsiki N, Tziomalos K, Chatzizisis Y, Elisaf M, Hatzitolios AI: Effect of HMG-CoA reductase inhibitors on vascular cell apoptosis: beneficial or detrimental? Atherosclerosis, 2010; 211: 9-14","DOI":"10.1016\/j.atherosclerosis.2009.12.028"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Isusi E, Aspichueta P, Liza M, Hern\u00e1ndez ML, D\u00edaz C, Hern\u00e1ndez G, Mart\u00ednez MJ, Ochoa B: Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. Atherosclerosis, 2000; 153: 283-294","DOI":"10.1016\/S0021-9150(00)00407-X"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Bonetti PO, Lerman LO, Napoli C, Lerman A: Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J, 2003; 24: 225-248","DOI":"10.1016\/S0195-668X(02)00419-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Pontrelli L, Parris W, Adeli K, Cheung RC: Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose\/type 2 diabetes. Metabolism, 2002; 51: 334-342","DOI":"10.1053\/meta.2002.30510"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) \u00d6\u00f6rni K, Sneck M, Br\u00f6mme D, Pentik\u00e4inen MO, Lindstedt KA, M\u00e4yr\u00e4np\u00e4\u00e4 M, Aitio H, Kovanen PT: Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem, 2004; 279: 34776-34784","DOI":"10.1074\/jbc.M310814200"},{"key":"31","unstructured":"31) Rizzo M, Berneis K, Zeljkovic A, Vekic J: Should we routinely measure low-density and high-density lipoprotein subclasses? Clin Lab, 2009; 55: 421-429"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS: Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol, 2008; 590: 327-332","DOI":"10.1016\/j.ejphar.2008.06.007"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Kostapanos MS, Milionis HJ, Filippatos TD, Christogiannis LG, Bairaktari ET, Tselepis AD, Elisaf MS: Dosedependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther, 2009; 14: 5-13","DOI":"10.1177\/1074248408331031"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JA, Seman LJ, Ferrari A, Rubenstein JJ: Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol, 2002; 90: 689-696","DOI":"10.1016\/S0002-9149(02)02591-2"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kontush A, Chapman MJ: Functionally defective highdensity-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev, 2006; 58: 342-374","DOI":"10.1124\/pr.58.3.1"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, Fuller JH, Julier K, Mackness MI, Neil HA: The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis, 2003; 167: 243-255","DOI":"10.1016\/S0021-9150(02)00428-8"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Kontush A, Chapman MJ: Antiatherogenic small, dense HDL-guardian angel of the artherial wall? Nat Clin Pract Cardiovas Med, 2006; 3: 144-156","DOI":"10.1038\/ncpcardio0500"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) de Souza JA, Vindis C, Hansel B, Negre-Salvayre A, Therond P, Serrano CV Jr, Chantepie S, Salvayre R, Bruckert E, Chapman MJ, Kontush A: Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atheroslerosis, 2008; 197: 84-94","DOI":"10.1016\/j.atherosclerosis.2007.08.009"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Musunuru K, Orho-Melander M, Caulfield MP, Li S, Salameh WA, Reitz RE, Berglund G, Hedblad B, Engstr\u00f6m G, Williams PT, Kathiresan S, Melander O, Krauss RM: Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol, 2009; 29: 1975-1980","DOI":"10.1161\/ATVBAHA.109.190405"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T15:17:10Z","timestamp":1648826230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/21\/8\/21_21410\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.21410","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}